StockData
PROCEPT BioRobotics Corp logo

PROCEPT BioRobotics Corp (PRCT) stock

PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/3051% below fair value
$23.51+0.17 (+0.73%)

Close on Nov 12, 2026Market cap $1.35BP/E –Yield –

Earnings

PROCEPT BioRobotics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$98.30M
+18.0% on a year earlier
EPS, Q3 FY2026
-$0.46
Latest guidance
Issued
Nov 4, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of PROCEPT BioRobotics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$98.30M+18.0%-$0.46Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026after the close$94.50M+19.3%-$0.47Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026after the close$83.10M+20.1%–Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close$76.40M+12.0%–Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$83.30M+42.6%–Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$79.20M+48.3%-$0.35Release
Q1 FY2025ended Mar 31, 2025Apr 24, 2025before the open$69.20M––Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025after the close$68.20M––Release
Q3 FY2024ended Sep 30, 2024Oct 28, 2024before the open$58.40M+66.4%–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$53.40M+61.3%-$0.50Release
Q1 FY2024ended Mar 31, 2024May 1, 2024before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

PROCEPT BioRobotics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$390.00M – $410.00M–NewNov 4, 2026
revenueFY2026$390.00M – $410.00M$390.00M – $410.00MReaffirmedAug 4, 2026
revenue growthFY2026+27% – +33%+27% – +33%ReaffirmedApr 29, 2026
gross marginFY202665%–NewNov 4, 2026
gross marginFY202665%65%ReaffirmedAug 4, 2026
adjusted EBITDAnon-GAAPFY2026-$35.00M – -$30.00M-$30.00M – -$17.00MLoweredAug 4, 2026
adjusted EBITDA lossnon-GAAPFY2026-$35.00M – -$30.00M–NewNov 4, 2026
operating expensesFY2026$350.00M–NewFeb 25, 2026
U.S. procedure growthFY2026+39% – +48%+39% – +48%ReaffirmedApr 29, 2026
U.S. procedure volumeFY202654,000 – 56,000–NewNov 4, 2026
U.S. procedure volumeFY202654,000 – 56,000–NewAug 4, 2026

Guidance vs results

The last range PROCEPT BioRobotics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2026Revenue$79.00M – $82.00M$83.10MAbove range
Q1 FY2026Revenue growth+14% – +19%+20.09%Above range
FY2025Revenue$325.50M$308.10MΣ4QBelow range
Q1 FY2025Revenue$65.50M$69.20MAbove range
Q1 FY2022Revenue$12.00M – $12.50M$14.20MAbove range

Guidance history

Every forecast PROCEPT BioRobotics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026adjusted EBITDA lossFY2026-$35.00M – -$30.00MNew
Nov 4, 2026gross marginFY202665%New
Nov 4, 2026U.S. procedure volumeFY202654,000 – 56,000New
Nov 4, 2026revenueFY2026$390.00M – $410.00MNew
Aug 4, 2026adjusted EBITDAFY2026-$35.00M – -$30.00MLowered
Aug 4, 2026gross marginFY202665%Reaffirmed
Aug 4, 2026U.S. procedure volumeFY202654,000 – 56,000New
Aug 4, 2026revenueFY2026$390.00M – $410.00MReaffirmed
Apr 29, 2026adjusted EBITDA lossFY2026-$30.00M – -$17.00MReaffirmed
Apr 29, 2026gross marginFY202665%Reaffirmed
Apr 29, 2026U.S. procedure growthFY2026+39% – +48%Reaffirmed
Apr 29, 2026revenue growthFY2026+27% – +33%Reaffirmed
Apr 29, 2026revenueFY2026$390.00M – $410.00MReaffirmed
Feb 25, 2026adjusted EBITDA* lossFY2026-$30.00M – -$17.00MNew
Feb 25, 2026gross marginFY202665%New
Feb 25, 2026operating expensesFY2026$350.00MNew
Feb 25, 2026U.S. procedure growthFY2026+39% – +48%New
Feb 25, 2026total proceduresQ1 FY202612,000 – 12,800New
Feb 25, 2026growthQ1 FY2026+31% – +36%New
Feb 25, 2026annual growthFY2026+27% – +33%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases PROCEPT BioRobotics filed with the SEC as exhibits to Form 8-K or 6-K

  1. PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
    Results
  2. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
    Results
  3. PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
    Results
  4. 8-K exhibit EX-99.1
    Update
  5. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
    Results
  6. PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
    Results
  7. PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
    Results
  8. PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
    Results
  9. 8-K exhibit EX-99.1
    Update
  10. PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
    Results
  11. PROCEPT BioRobotics ® Reports Fourth Quarter and Full Year 2024 Results
    Results
  12. PROCEPT BioRobotics ® Reports Third Quarter 2024 Financial Results and
    Results
  13. PROCEPT BioRobotics ® Reports Second Quarter 2024 Financial Results and
    Results
  14. 8-K exhibit EX-99.1
    Update
  15. PROCEPT BioRobotics ® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
    Results

See a number that looks wrong?